129 related articles for article (PubMed ID: 14612139)
1. The top 20 dopamine transporter mutants: structure-function relationships and cocaine actions.
Uhl GR; Lin Z
Eur J Pharmacol; 2003 Oct; 479(1-3):71-82. PubMed ID: 14612139
[TBL] [Abstract][Full Text] [Related]
2. Dopamine transporter tryptophan mutants highlight candidate dopamine- and cocaine-selective domains.
Lin Z; Wang W; Uhl GR
Mol Pharmacol; 2000 Dec; 58(6):1581-92. PubMed ID: 11093799
[TBL] [Abstract][Full Text] [Related]
3. Dopamine transporter: transmembrane phenylalanine mutations can selectively influence dopamine uptake and cocaine analog recognition.
Lin Z; Wang W; Kopajtic T; Revay RS; Uhl GR
Mol Pharmacol; 1999 Aug; 56(2):434-47. PubMed ID: 10419565
[TBL] [Abstract][Full Text] [Related]
4. Recognition of benztropine by the dopamine transporter (DAT) differs from that of the classical dopamine uptake inhibitors cocaine, methylphenidate, and mazindol as a function of a DAT transmembrane 1 aspartic acid residue.
Ukairo OT; Bondi CD; Newman AH; Kulkarni SS; Kozikowski AP; Pan S; Surratt CK
J Pharmacol Exp Ther; 2005 Aug; 314(2):575-83. PubMed ID: 15879005
[TBL] [Abstract][Full Text] [Related]
5. Mutation of Trp84 and Asp313 of the dopamine transporter reveals similar mode of binding interaction for GBR12909 and benztropine as opposed to cocaine.
Chen N; Zhen J; Reith ME
J Neurochem; 2004 May; 89(4):853-64. PubMed ID: 15140185
[TBL] [Abstract][Full Text] [Related]
6. Dopamine transporter proline mutations influence dopamine uptake, cocaine analog recognition, and expression.
Lin Z; Itokawa M; Uhl GR
FASEB J; 2000 Apr; 14(5):715-28. PubMed ID: 10744628
[TBL] [Abstract][Full Text] [Related]
7. Dopamine transporter mutants with cocaine resistance and normal dopamine uptake provide targets for cocaine antagonism.
Lin Z; Uhl GR
Mol Pharmacol; 2002 Apr; 61(4):885-91. PubMed ID: 11901228
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference.
Sora I; Hall FS; Andrews AM; Itokawa M; Li XF; Wei HB; Wichems C; Lesch KP; Murphy DL; Uhl GR
Proc Natl Acad Sci U S A; 2001 Apr; 98(9):5300-5. PubMed ID: 11320258
[TBL] [Abstract][Full Text] [Related]
9. Dopamine transporter transmembrane domain polar mutants: DeltaG and DeltaDeltaG values implicate regions important for transporter functions.
Itokawa M; Lin Z; Cai NS; Wu C; Kitayama S; Wang JB; Uhl GR
Mol Pharmacol; 2000 Jun; 57(6):1093-103. PubMed ID: 10825379
[TBL] [Abstract][Full Text] [Related]
10. A triple mutation in the second transmembrane domain of mouse dopamine transporter markedly decreases sensitivity to cocaine and methylphenidate.
Chen R; Han DD; Gu HH
J Neurochem; 2005 Jul; 94(2):352-9. PubMed ID: 15998286
[TBL] [Abstract][Full Text] [Related]
11. Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters.
Shen HW; Hagino Y; Kobayashi H; Shinohara-Tanaka K; Ikeda K; Yamamoto H; Yamamoto T; Lesch KP; Murphy DL; Hall FS; Uhl GR; Sora I
Neuropsychopharmacology; 2004 Oct; 29(10):1790-9. PubMed ID: 15226739
[TBL] [Abstract][Full Text] [Related]
12. Dual probes for the dopamine transporter and sigma1 receptors: novel piperazinyl alkyl-bis(4'-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents.
Cao J; Kulkarni SS; Husbands SM; Bowen WD; Williams W; Kopajtic T; Katz JL; George C; Newman AH
J Med Chem; 2003 Jun; 46(13):2589-98. PubMed ID: 12801223
[TBL] [Abstract][Full Text] [Related]
13. Molecular model of the neural dopamine transporter.
Ravna AW; Sylte I; Dahl SG
J Comput Aided Mol Des; 2003; 17(5-6):367-82. PubMed ID: 14635728
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms underlying the rewarding effects of cocaine.
Hall FS; Sora I; Drgonova J; Li XF; Goeb M; Uhl GR
Ann N Y Acad Sci; 2004 Oct; 1025():47-56. PubMed ID: 15542699
[TBL] [Abstract][Full Text] [Related]
15. The interaction of methylphenidate and benztropine with the dopamine transporter is different than other substrates and ligands.
Dar DE; Mayo C; Uhl GR
Biochem Pharmacol; 2005 Aug; 70(3):461-9. PubMed ID: 15950948
[TBL] [Abstract][Full Text] [Related]
16. Proline mutations induce negative-dosage effects on uptake velocity of the dopamine transporter.
Lin Z; Uhl GR
J Neurochem; 2005 Jul; 94(1):276-87. PubMed ID: 15953370
[TBL] [Abstract][Full Text] [Related]
17. Studies of the biogenic amine transporters. 10. Characterization of a novel cocaine binding site in brain membranes prepared from dopamine transporter knockout mice.
Rothman RB; Carroll FI; Morales M; Rowley DL; Rice KC; Dersch CM; Donovan DM
Synapse; 2002 May; 44(2):94-105. PubMed ID: 11891881
[TBL] [Abstract][Full Text] [Related]
18. The functional domains of dopamine transporter for cocaine analog, CFT binding.
Lee SH; Chang MY; Jeon DJ; Oh DY; Son H; Lee CH; Lee YS; Lee YS
Exp Mol Med; 2002 Mar; 34(1):90-4. PubMed ID: 11989984
[TBL] [Abstract][Full Text] [Related]
19. Dissociation of high-affinity cocaine analog binding and dopamine uptake inhibition at the dopamine transporter.
Wang W; Sonders MS; Ukairo OT; Scott H; Kloetzel MK; Surratt CK
Mol Pharmacol; 2003 Aug; 64(2):430-9. PubMed ID: 12869648
[TBL] [Abstract][Full Text] [Related]
20. Highly selective, novel analogs of 4-[2-(diphenylmethoxy)ethyl]- 1-benzylpiperidine for the dopamine transporter: effect of different aromatic substitutions on their affinity and selectivity.
Dutta AK; Coffey LL; Reith ME
J Med Chem; 1997 Jan; 40(1):35-43. PubMed ID: 9016326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
